179 related articles for article (PubMed ID: 28004415)
1. Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study.
Feng T; Howard LE; Vidal AC; Moreira DM; Castro-Santamaria R; Andriole GL; Freedland SJ
Int J Urol; 2017 Feb; 24(2):151-156. PubMed ID: 28004415
[TBL] [Abstract][Full Text] [Related]
2. Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial.
Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal AC; Castro-Santamaria R; Freedland SJ
Eur Urol; 2016 May; 69(5):885-91. PubMed ID: 26724841
[TBL] [Abstract][Full Text] [Related]
3. Statin Use and Lower Urinary Tract Symptoms Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
Kramer JJ; Gu L; Moreira D; Andriole G; Csizmadi I; Freedland SJ
J Urol; 2022 Feb; 207(2):417-423. PubMed ID: 34544265
[TBL] [Abstract][Full Text] [Related]
4. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.
Toren P; Margel D; Kulkarni G; Finelli A; Zlotta A; Fleshner N
BMJ; 2013 Apr; 346():f2109. PubMed ID: 23587564
[TBL] [Abstract][Full Text] [Related]
5. Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE.
Simon RM; Howard LE; Moreira DM; Roehrborn C; Vidal A; Castro-Santamaria R; Freedland SJ
J Urol; 2017 Sep; 198(3):650-656. PubMed ID: 28428110
[TBL] [Abstract][Full Text] [Related]
6. Smoking and lower urinary tract symptoms in Reduction by Dutasteride of Prostate Cancer Events Trial.
Kramer JJ; Gu L; Moreira D; Andriole G; Freedland SJ; Csizmadi I
Prostate; 2023 Jul; 83(10):990-997. PubMed ID: 37070723
[TBL] [Abstract][Full Text] [Related]
7. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
8. Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention.
Nickel JC; Roehrborn CG; Castro-Santamaria R; Freedland SJ; Moreira DM
J Urol; 2016 Nov; 196(5):1493-1498. PubMed ID: 27378134
[TBL] [Abstract][Full Text] [Related]
9. Early effect of dutasteride added to alpha-1 blocker therapy for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
Araki K; Naya Y; Inahara M; Suzuki F; Ota S; Tsuji H; Mikami K; Yanagisawa M; Awa Y; Suzuki H
Int J Urol; 2014 Aug; 21(8):815-9. PubMed ID: 24735081
[TBL] [Abstract][Full Text] [Related]
10. Serum Testosterone and Dihydrotestosterone and Incidence and Progression of Lower Urinary Tract Symptoms: Results From the REDUCE Study.
Daniels JP; Mirocha J; Adjei M; Moreira D; Freedland SJ
J Urol; 2024 Jan; 211(1):101-110. PubMed ID: 37873943
[TBL] [Abstract][Full Text] [Related]
11. Intravesical Prostatic Protrusion as a Predicting Factor for the Adverse Clinical Outcome in Patients With Symptomatic Benign Prostatic Enlargement Treated With Dutasteride.
Yoshida T; Kinoshita H; Yoshida K; Mishima T; Taniguchi H; Yanishi M; Komai Y; Yasuda K; Sugi M; Matsuda T
Urology; 2016 May; 91():154-7. PubMed ID: 26826590
[TBL] [Abstract][Full Text] [Related]
12. Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction.
Traish A; Haider KS; Doros G; Haider A
Horm Mol Biol Clin Investig; 2017 Jun; 30(3):. PubMed ID: 28632494
[TBL] [Abstract][Full Text] [Related]
13. Effects of dutasteride on lower urinary tract symptoms: a prospective analysis based on changes in testosterone/dihydrotestosterone levels and total prostatic volume reduction.
Shigehara K; Miyagi T; Nakashima T; Izumi K; Kitagawa Y; Mizokami A; Koh E; Shimamura M; Namiki M
Aging Male; 2016 Jun; 19(2):128-33. PubMed ID: 26890877
[TBL] [Abstract][Full Text] [Related]
14. PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study.
Patel DN; Feng T; Simon RM; Howard LE; Vidal AC; Moreira DM; Castro-Santamaria R; Roehrborn C; Andriole GL; Freedland SJ
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):238-244. PubMed ID: 29795141
[TBL] [Abstract][Full Text] [Related]
15. Sleep Problems are Associated with Development and Progression of Lower Urinary Tract Symptoms: Results from REDUCE.
Branche BL; Howard LE; Moreira DM; Roehrborn C; Castro-Santamaria R; Andriole GL; Hopp ML; Freedland SJ
J Urol; 2018 Feb; 199(2):536-542. PubMed ID: 28870861
[TBL] [Abstract][Full Text] [Related]
16. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
17. Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.
Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Palacios JM; Vasylyev A; Manyak MJ
World J Urol; 2017 Mar; 35(3):421-427. PubMed ID: 27334136
[TBL] [Abstract][Full Text] [Related]
18. Finasteride or dutasteride for the pharmacological treatment for male lower urinary tract symptoms due to benign prostatic hyperplasia?
Alcántara-Montero A; Brenes-Bermúdez FJ
Actas Urol Esp; 2016 May; 40(4):268-9. PubMed ID: 26774534
[No Abstract] [Full Text] [Related]
19. Dutasteride Improves Nocturia but Does Not Lead to Better Sleep: Results from the REDUCE Clinical Trial.
Kuhlmann PK; Fischer SC; Howard LE; Moreira DM; Andriole GL; Hopp ML; Roehrborn CG; Bliwise DL; Freedland SJ
J Urol; 2021 Jun; 205(6):1733-1739. PubMed ID: 33605791
[TBL] [Abstract][Full Text] [Related]
20. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
